-- Sarepta Therapeutics (SRPT) could benefit from Roche's new late-stage Elevidys study, stronger US demand in the second half of 2026, steady sales and possible regulatory progress for key exon-skipping drugs, Wedbush said in a note Friday.
Roche's plan to start a new global phase 3 trial outside the US signals confidence in Elevidys and should not affect the therapy's US commercialization, though Elevidys revenue in the first half of 2026 could stay soft, the investment firm said.
Wedbush said feedback from key opinion leaders points to better uptake in the second half of 2026 as doctors remain positive on Elevidys in ambulatory patients.
Data due by the end of 2026 from non-ambulatory patients in Cohort 8 of the ENDEAVOR study could improve confidence in the drug's safety if the results are positive, according to the note.
Wedbush maintained its outperform rating and $35 price target for Sarepta, adding that phosphorodiamidate morpholino oligomer sales should remain stable in 2026, with an update on filings for Amondys 45 and Vyondys 53 expected by the end of the second quarter.
Price: $21.30, Change: $+0.13, Percent Change: +0.59%